275 related articles for article (PubMed ID: 30367064)
1. Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45.
Kundu P; Semesi A; Jore MM; Morin MJ; Price VL; Liang A; Li J; Miura K; Sauerwein RW; King CR; Julien JP
Nat Commun; 2018 Oct; 9(1):4458. PubMed ID: 30367064
[TBL] [Abstract][Full Text] [Related]
2. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
[TBL] [Abstract][Full Text] [Related]
3. A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies.
Singh SK; Roeffen W; Andersen G; Bousema T; Christiansen M; Sauerwein R; Theisen M
Vaccine; 2015 Apr; 33(16):1981-6. PubMed ID: 25728318
[TBL] [Abstract][Full Text] [Related]
4. Fusion to Tetrahymena thermophila granule lattice protein 1 confers solubility to sexual stage malaria antigens in Escherichia coli.
Agrawal A; Bisharyan Y; Papoyan A; Bednenko J; Cardarelli J; Yao M; Clark T; Berkmen M; Ke N; Colussi P
Protein Expr Purif; 2019 Jan; 153():7-17. PubMed ID: 30081196
[TBL] [Abstract][Full Text] [Related]
5. Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins.
Singh K; Burkhardt M; Nakuchima S; Herrera R; Muratova O; Gittis AG; Kelnhofer E; Reiter K; Smelkinson M; Veltri D; Swihart BJ; Shimp R; Nguyen V; Zhang B; MacDonald NJ; Duffy PE; Garboczi DN; Narum DL
Commun Biol; 2020 Jul; 3(1):395. PubMed ID: 32709983
[TBL] [Abstract][Full Text] [Related]
6. Geographical distribution of a variant epitope of Pfs48/45, a Plasmodium falciparum transmission-blocking vaccine candidate.
Drakeley CJ; Duraisingh MT; Póvoa M; Conway DJ; Targett GA; Baker DA
Mol Biochem Parasitol; 1996 Oct; 81(2):253-7. PubMed ID: 8898341
[No Abstract] [Full Text] [Related]
7. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD
Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
[TBL] [Abstract][Full Text] [Related]
8. Structure and Characterisation of a Key Epitope in the Conserved C-Terminal Domain of the Malaria Vaccine Candidate MSP2.
Seow J; Morales RA; MacRaild CA; Krishnarjuna B; McGowan S; Dingjan T; Jaipuria G; Rouet R; Wilde KL; Atreya HS; Richards JS; Anders RF; Christ D; Drinkwater N; Norton RS
J Mol Biol; 2017 Mar; 429(6):836-846. PubMed ID: 28189425
[TBL] [Abstract][Full Text] [Related]
9. Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies.
Triller G; Scally SW; Costa G; Pissarev M; Kreschel C; Bosch A; Marois E; Sack BK; Murugan R; Salman AM; Janse CJ; Khan SM; Kappe SHI; Adegnika AA; Mordmüller B; Levashina EA; Julien JP; Wardemann H
Immunity; 2017 Dec; 47(6):1197-1209.e10. PubMed ID: 29195810
[TBL] [Abstract][Full Text] [Related]
10.
Singh SK; Thrane S; Chourasia BK; Teelen K; Graumans W; Stoter R; van Gemert GJ; van de Vegte-Bolmer MG; Nielsen MA; Salanti A; Sander AF; Sauerwein RW; Jore MM; Theisen M
Front Immunol; 2019; 10():1256. PubMed ID: 31231386
[TBL] [Abstract][Full Text] [Related]
11. A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes.
Coelho CH; Tang WK; Burkhardt M; Galson JD; Muratova O; Salinas ND; Alves E Silva TL; Reiter K; MacDonald NJ; Nguyen V; Herrera R; Shimp R; Narum DL; Byrne-Steele M; Pan W; Hou X; Brown B; Eisenhower M; Han J; Jenkins BJ; Doritchamou JYA; Smelkinson MG; Vega-Rodríguez J; Trück J; Taylor JJ; Sagara I; Healy SA; Renn JP; Tolia NH; Duffy PE
Nat Commun; 2021 Mar; 12(1):1750. PubMed ID: 33741942
[TBL] [Abstract][Full Text] [Related]
12. Structural vaccinology of malaria transmission-blocking vaccines.
Patel PN; Tolia N
Expert Rev Vaccines; 2021 Feb; 20(2):199-214. PubMed ID: 33430656
[No Abstract] [Full Text] [Related]
13. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.
Theisen M; Jore MM; Sauerwein R
Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178
[TBL] [Abstract][Full Text] [Related]
14. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based
Singh SK; Plieskatt J; Chourasia BK; Fabra-García A; Garcia-Senosiain A; Singh V; Bengtsson KL; Reimer JM; Sauerwein R; Jore MM; Theisen M
Front Immunol; 2020; 11():606266. PubMed ID: 33505395
[TBL] [Abstract][Full Text] [Related]
15. A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system.
Lee SM; Hickey JM; Miura K; Joshi SB; Volkin DB; King CR; Plieskatt JL
Sci Rep; 2020 Jan; 10(1):395. PubMed ID: 31942034
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of an inhibitory monoclonal antibody-defined epitope on a malaria vaccine candidate antigen.
Ramasamy R; Jones G; Lord R
Immunol Lett; 1990 Feb; 23(4):305-9. PubMed ID: 1693361
[TBL] [Abstract][Full Text] [Related]
17. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.
Dutta S; Dlugosz LS; Drew DR; Ge X; Ababacar D; Rovira YI; Moch JK; Shi M; Long CA; Foley M; Beeson JG; Anders RF; Miura K; Haynes JD; Batchelor AH
PLoS Pathog; 2013; 9(12):e1003840. PubMed ID: 24385910
[TBL] [Abstract][Full Text] [Related]
18. A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial.
Alkema M; Smit MJ; Marin-Mogollon C; Totté K; Teelen K; van Gemert GJ; van de Vegte-Bolmer M; Mordmüller BG; Reimer JM; Lövgren-Bengtsson KL; Sauerwein RW; Bousema T; Plieskatt J; Theisen M; Jore MM; McCall MBB
BMC Med; 2024 Apr; 22(1):170. PubMed ID: 38649867
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody.
Lennartz F; Brod F; Dabbs R; Miura K; Mekhaiel D; Marini A; Jore MM; Søgaard MM; Jørgensen T; de Jongh WA; Sauerwein RW; Long CA; Biswas S; Higgins MK
Nat Commun; 2018 Sep; 9(1):3822. PubMed ID: 30237518
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Plasmodium falciparum transmission reducing immunity among primary school children in a malaria moderate transmission region in Zimbabwe.
Paul NH; Vengesai A; Mduluza T; Chipeta J; Midzi N; Bansal GP; Kumar N
Acta Trop; 2016 Nov; 163():103-8. PubMed ID: 27491342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
